P1005: EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING

• Subbaiah Chary Nimmagadda,
• Paulina Marie Budde,
• Kaiyan Sun,
• Todd Covey,
• Cecile Krejsa,
• Wayne P. Rothbaum,
• Nikolas von Bubnoff,
• Cyrus Khandanpour

Affiliations

Subbaiah Chary Nimmagadda

1 University Hospital Münster, Münster, Germany

Paulina Marie Budde

1 University Hospital Münster, Münster, Germany

Kaiyan Sun

1 University Hospital Münster, Münster, Germany

Todd Covey

3 Telios Pharma Inc.,, Redwood City, CA, United States

Cecile Krejsa

3 Telios Pharma Inc.,, Redwood City, CA, United States

Wayne P. Rothbaum

3 Telios Pharma Inc.,, Redwood City, CA, United States

Nikolas von Bubnoff

2 University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

Cyrus Khandanpour

1 University Hospital Münster, Münster, Germany